Literature DB >> 9623168

[Optimization of the antibiotics policy in the Netherlands. II. SWAB guidelines for the antimicrobial therapy of pneumonia in patients at home and as nosocomial infections. The Netherlands Antibiotic Policy Foundation].

M E van Kasteren1, W J Wijnands, E E Stobberingh, R Janknegt, J W van der Meer.   

Abstract

The Netherlands Antibiotic Policy Foundation issued guidelines for empirical antimicrobial therapy of adult pneumonia patients in hospitals. A distinction is made between pneumonia contracted at home or in hospital because of the differences in micro-organisms and resistance patterns. These two categories are subdivided further with an empirical antibiotic treatment being chosen on the basis of the causative agents to be expected. For instance, pneumonia contracted at home is mostly caused by Streptococcus pneumoniae, to be treated with benzylpenicillin or amoxicillin. With regard to nosocomial pneumonia, treatment varies according to whether a pneumonia has or has not been contracted in the intensive care unit. Combating development of resistance is alloted an important place. Emphasis is laid on 'streamlining' the therapy, i.e. its adjustment (including choosing an antibiotic with the narrowest possible spectrum) once the causative agent is known.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9623168

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  7 in total

1.  Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study.

Authors:  W S Lim; M M van der Eerden; R Laing; W G Boersma; N Karalus; G I Town; S A Lewis; J T Macfarlane
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  Limited effect of patient and disease characteristics on compliance with hospital antimicrobial guidelines.

Authors:  Peter G M Mol; Petra Denig; Rijk O B Gans; Prashant V Nannanpanday; John E Degener; Marian Laseur; Flora M Haaijer-Ruskamp
Journal:  Eur J Clin Pharmacol       Date:  2006-01-24       Impact factor: 2.953

3.  Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study.

Authors:  M M van der Eerden; F Vlaspolder; C S de Graaff; T Groot; W Bronsveld; H M Jansen; W G Boersma
Journal:  Thorax       Date:  2005-08       Impact factor: 9.139

4.  Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia.

Authors:  M M van der Eerden; F Vlaspolder; C S de Graaff; T Groot; H M Jansen; W G Boersma
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-04       Impact factor: 3.267

5.  Barriers to optimal antibiotic use for community-acquired pneumonia at hospitals: a qualitative study.

Authors:  Jeroen A Schouten; Marlies E J L Hulscher; Stephanie Natsch; Bart-Jan Kullberg; Jos W M van der Meer; Richard P T M Grol
Journal:  Qual Saf Health Care       Date:  2007-04

6.  Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial.

Authors:  Jan Jelrik Oosterheert; Marc J M Bonten; Margriet M E Schneider; Erik Buskens; Jan-Willem J Lammers; Willem M N Hustinx; Mark H H Kramer; Jan M Prins; Peter H Th J Slee; Karin Kaasjager; Andy I M Hoepelman
Journal:  BMJ       Date:  2006-11-07

7.  Algorithm to determine cost savings of targeting antimicrobial therapy based on results of rapid diagnostic testing.

Authors:  J J Oosterheert; M J M Bonten; E Buskens; M M E Schneider; I M Hoepelman
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.